<DOC>
	<DOCNO>NCT02901951</DOCNO>
	<brief_summary>The purpose study ass long-term protection HBV infection adult subject , age 18-40 year vaccinate three four dos Engerix-B 20 30 year ago</brief_summary>
	<brief_title>Long-term Persistence Immunity Hepatitis B Adults Vaccinated With GlaxoSmithKline ( GSK ) Biologicals ' Hepatitis B Vaccine ( HBV ) , Engerix™-B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol . A male female include 40 60 year age ( include 40th birthday , exclude , 61st birthday ) time vaccination . Written inform consent obtain subject . Documented evidence previous vaccination three four consecutive dos EngerixB administer adulthood ( i.e . least 18 year age ) last dose receive 4 12 month previous one , subsequent booster dose ever receive later , last dose receive 20 30 year enrolment . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period one month vaccination . Use investigational nonregistered product study vaccine period start 30 day dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior vaccine dose . For corticosteroid , mean prednisone ≥ 20 mg/day , equivalent . Inhaled topical steroid allow . Administration longacting immunemodifying drug time study period . Previous hepatitis B booster vaccination since completion primary vaccination series three four dos EngerixB . Planned administration vaccine foreseen study protocol within 30 day precede dose study vaccine , plan administration study period , exception seasonal influenza vaccine . Any medical condition judgment investigator place subject undue risk participate study . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . History hepatitis B disease episode jaundice unknown etiology . History reaction hypersensitivity likely exacerbate component vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Major congenital defect serious chronic illness ( include insulindependent diabetes ) . Acute disease and/or fever time enrolment . Fever define temperature ≥37.5°C oral , axillary tympanic route , 38.0°C rectal route . Subjects minor illness without fever may enrol discretion investigator . Administration immunoglobulins and/or blood product period start 3 month dose study vaccine , plan administration study period . Drug and/ alcohol abuse within last 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adult subject</keyword>
	<keyword>Hepatitis B antibody</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>HBV</keyword>
</DOC>